# Chiesi Farmaceutici S.p.A. clinical trials: 185 (2026)

ClinicalTrials.gov lists 185 trials with Chiesi Farmaceutici S.p.A. as lead sponsor, 21 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Chiesi Farmaceutici S.p.A.: 185 rows for $9.25, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/chiesi-farmaceutici-s-p-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 185
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 25 newest of 185, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 15, 2026 | NCT07876284 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic... | Chiesi Farmaceutici S.p.A. | Phase 1 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876284) |
| October 5, 2026 | NCT07858123 | Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma | Chiesi Farmaceutici S.p.A. | Phase 3 | Not yet recruiting | Asthma | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858123) |
| October 1, 2026 | NCT07851623 | Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults... | Chiesi Farmaceutici S.p.A. | Phase 1 | Recruiting | Asthma, Healthy Volunteers | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851623) |
| August 4, 2026 | NCT07744386 | A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines... | Chiesi Farmaceutici S.p.A. | Phase 1 | Not yet recruiting | Healthy Male Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744386) |
| July 6, 2026 | NCT07683793 | A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in... | Chiesi Farmaceutici S.p.A. | Phase 1 | Not yet recruiting | Healthy Volunteers | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683793) |
| June 24, 2026 | NCT07666490 | BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI \[BDP/FF/GB - 100/6/12.5 μg\]) vs Single Inhaler ICS/LABA... | Chiesi Farmaceutici S.p.A. | Phase 4 | Recruiting | Asthma | 644 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07666490) |
| May 11, 2026 | NCT07577804 | A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to... | Chiesi Farmaceutici S.p.A. | Phase 3 | Not yet recruiting | Bronchiectasis | 904 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07577804) |
| April 23, 2026 | NCT07546981 | Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids... | Chiesi Farmaceutici S.p.A. | Phase 3 | Recruiting | Asthma | 554 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546981) |
| April 8, 2026 | NCT07516951 | A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis | Chiesi Farmaceutici S.p.A. | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516951) |
| December 24, 2025 | NCT07301736 | Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | Chiesi Farmaceutici S.p.A. | Phase 2 | Recruiting | Asthma | 780 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301736) |
| September 9, 2025 | NCT07163182 | Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy... | Chiesi Farmaceutici S.p.A. | Phase 1 | Recruiting | Healthy Volunteers | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07163182) |
| April 23, 2025 | NCT06941025 | Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease... | Chiesi Farmaceutici S.p.A. | Observational | Recruiting | Fabry Disease, Pregnancy, Pregnancy Complications | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06941025) |
| April 8, 2025 | NCT06917690 | A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa | Chiesi Farmaceutici S.p.A. | Phase 3 | Recruiting | Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06917690) |
| March 28, 2025 | NCT06900816 | A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 | Chiesi Farmaceutici S.p.A. | Phase 2 | Completed | Asthma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06900816) |
| March 25, 2025 | NCT06892756 | Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug... | Chiesi Farmaceutici S.p.A. | Phase 1 | Completed | Chronic Obstructive Pulmonary Disease (COPD) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06892756) |
| December 24, 2024 | NCT06746064 | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy... | Chiesi Farmaceutici S.p.A. | Phase 1 | Completed | Pulmonary Fibrosis | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06746064) |
| November 7, 2024 | NCT06679270 | Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy | Chiesi Farmaceutici S.p.A. | Phase 3 | Recruiting | Familial Partial Lipodystrophy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06679270) |
| October 29, 2024 | NCT06663358 | A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients | Chiesi Farmaceutici S.p.A. | Observational | Recruiting | Fabry Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06663358) |
| June 28, 2024 | NCT06480890 | Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY) | Chiesi Farmaceutici S.p.A. | Observational | Completed | Chronic Obstructive Pulmonary Disease | 362 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06480890) |
| May 21, 2024 | NCT06423573 | A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez | Chiesi Farmaceutici S.p.A. | Observational | Recruiting | Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06423573) |
| May 2, 2024 | NCT06395610 | Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers | Chiesi Farmaceutici S.p.A. | Phase 1 | Completed | Chronic Obstructive Pulmonary Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06395610) |
| March 25, 2024 | NCT06328608 | A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease | Chiesi Farmaceutici S.p.A. | Phase 2/3 | Recruiting | Fabry Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06328608) |
| February 20, 2024 | NCT06264674 | Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). | Chiesi Farmaceutici S.p.A. | Phase 3 | Completed | Asthma | 827 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06264674) |
| December 28, 2023 | NCT06184503 | Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3 | Chiesi Farmaceutici S.p.A. | Observational | Recruiting | Alpha-Mannosidosis | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06184503) |
| December 12, 2023 | NCT06166056 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After... | Chiesi Farmaceutici S.p.A. | Phase 1/2 | Completed | Bronchiectasis | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06166056) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 39 |
| Phase 1/2 | 6 |
| Phase 2 | 49 |
| Phase 2/3 | 2 |
| Phase 3 | 58 |
| Phase 4 | 10 |
| Not applicable | 3 |
| Observational | 18 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 143 |
| Recruiting | 16 |
| Terminated | 15 |
| Not yet recruiting | 5 |
| Withdrawn | 4 |
| Available | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Asthma | 62 |
| Pulmonary Disease, Chronic Obstructive | 61 |
| Fabry Disease | 8 |
| Cystic Fibrosis | 6 |
| alpha-Mannosidosis | 6 |
| Respiratory Distress Syndrome, Newborn | 4 |
| Respiratory Distress Syndrome | 4 |
| Idiopathic Pulmonary Fibrosis | 3 |
| Pulmonary Eosinophilia | 2 |
| Proteinuria | 2 |
| Respiratory Aspiration | 2 |
| Bronchiectasis | 2 |
| Bronchitis, Chronic | 2 |
| Lipodystrophy, Partial, Acquired | 2 |
| Epidermolysis Bullosa, Junctional | 2 |
| Epidermolysis Bullosa Dystrophica | 2 |
| Alzheimer Disease | 2 |
| Severe combined immunodeficiency due to adenosine deaminase deficiency | 1 |
| Croup | 1 |
| Pulmonary Fibrosis | 1 |
| Renal Insufficiency | 1 |
| Respiratory Sounds | 1 |
| Anthrax | 1 |
| Lipodystrophy, Familial Partial | 1 |
| Pregnancy Complications | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Telecommunications companies in the United States](https://specstream.ai/data/businesses/telecommunications-companies/united-states)
- [Flooring contractors in the United States](https://specstream.ai/data/businesses/flooring-contractors/united-states)
- [Tax law firms in the United States](https://specstream.ai/data/businesses/tax-law-firms/united-states)
- [Fish and chips restaurants in the United States](https://specstream.ai/data/businesses/fish-and-chips-restaurants/united-states)
- [Taco restaurants in the United States](https://specstream.ai/data/businesses/taco-restaurants/united-states)
- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
